Principles of growth hormone and insulin-like growth factor-I treatment in children with idiopathic short stature

Hormone Research in Paediatrics

Volumn 76, Issue SUPPL. 3, 2011, Pages 24-26

  Bang, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Combination treatment; Growth hormone; growth hormone; Idiopathic short stature; Insulin like growth factor I; Recombinant human

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

CHILDHOOD DISEASE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; EUROPEAN UNION; HORMONE DEFICIENCY; HORMONE RESISTANCE; HORMONE SUBSTITUTION; HUMAN; IDIOPATHIC DISEASE; PRIORITY JOURNAL; SHORT STATURE; SOMATOMEDIN C DEFICIENCY; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADULT; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; GROWTH DISORDERS; GROWTH PLATE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS; TREATMENT OUTCOME; UNITED STATES;

EID: 80052756225     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000330148     Document Type: Conference Paper

References (25)

1. Wit JM, Bang P: European perspective on treatment approaches for growth failure. Pediatr Endocrinol Rev 2008; 5(suppl 3):862-868.
2. Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, Crowe BJ, Ross JL, Cassorla FG, Blum WF, Cutler Jr GB, Baron J; National Institute of Child Health and Human Development-Eli Lilly and Co. Growth Hormone Collaborative Group: Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature. A randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 3140-3148. (Pubitemid 38960690)
3. Wit JM, Rekers-Mombarg LTM, Cutler Jr GB, Crowe BJ, Beck TJ, Gill AM, Chaussain J-L, Frishch H, Yturriaga R, Attanasio AF: Growth hormone (GH) treatment to final height in children with idiopathic short stature: Evidence for a dose effect. J Pediatr 2005; 146: 45-53. (Pubitemid 40091730)
4. Finkelstein B, Imperiale T, Speroff T, Marrero U, Radcliffe D, Cuttler L: The effect of growth hormone therapy on height in children with idiopathic short stature: A meta-analysis. Arch Pediatr Adolesc Med 2002; 156: 230-240. (Pubitemid 34205433)
5. Hintz RL, Attie KM, Baptista J, Roche A: Effect of growth hormone treatment on adult height in children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med 1999; 340: 502-507. (Pubitemid 29093285)
6. Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenäs L, Ivarsson SA, Jonsson B, Kriström B, Marcus C, Nilsson KO, Ritzén EM, Tuvemo T, Westphal O, Aman J: Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab 2008; 93: 4342-4350. (Pubitemid 352789530)
7. Kriström B, Dahlgren J, Niklasson A, Nierop AF, Albertsson-Wikland K: The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak 2009; 9: 1.
8. Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO: Short-term and long-term response to GH in ISS: KIGS analysis of factors predicting growth; in Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics - 20 Years of KIGS. Basel, Karger, 2007, pp 319-325.
9. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson- Wikland K, Price DA: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999; 84: 1174-1183. (Pubitemid 30644371)
10. Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K: Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab 2009; 94: 483-490.
11. Ranke MB, Price DA, Reiter EO (eds): Growth Hormone Therapy in Pediatrics - 20 Years of KIGS. Basel, Karger, 2007.
12. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM; 2007 ISS Consensus Workshop participants: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: A summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008; 93: 4210-4217. (Pubitemid 352806728)
13. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfelt RG: IGF-based dosing of GH therapy in children: A randomized controlled study. J Clin Endocrinol Metab 2007; 92: 2480-2486. (Pubitemid 47037346)
14. Bang P, Bjerknes R, Dahlgren J, Dunkel L, Gustafsson J, Juul A, Kristrom B, Tapanainen P, Aberg V: What is a poor growth response to rhGH therapy? A comparison of different definitions of growth response in 456 Nordic short statured children treated with rhGH. Horm Res 2009; 72(suppl 3):100(PO1-105). Program of the 8th Joint Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY (Abstract).
15. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE; GH Insensitivity Syndrome Collaborative Group: Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92: 902-910. (Pubitemid 46465661)
16. Walenkamp MJ, Wit JM: Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res 2006; 66: 221-230. (Pubitemid 44597720)
17. Ekström K, Salemyr J, Zachrisson I, Carlsson-Skwirut C, Ortqvist E, Bang P: Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes. Diabetes Care 2007; 30: 1357-1363. (Pubitemid 46871138)
18. Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB: Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein- 3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 4634-4641. (Pubitemid 39244481)
19. Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Gargosky S, Cohen P, Wilson K, Rosenfeld RG: Hormonal and metabolic effects and pharmacokinetics of recombinant insulinlike growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab 1993; 77: 273-280. (Pubitemid 23206815)
20. Ekström K, Carlsson-Skwirut C, Ritzén ME, Bang P: RhIGF-I therapy in combination with IGFBP-3 or alone in severe primary IGF-I deficiency (PIGFD) due to a GHR mutation (Laron syndrome): Effects on longitudinal growth, body composition and insulin sensitivity. Horm Res 2009; 72(suppl 3):112(PO1-136). Program of the 8th Joint Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY (Abstract).
21. Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM; MS301 Study Group: Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: First-year results from a randomized clinical trial. J Clin Endocrinol Metab 2010; 95: 611-619.
22. Rogers D, Gonzalez-Mendoza L, Soyka L, Frane JW, Bright GM: Safety and efficacy results of an 86-week, open label study of PK-based, oncedaily dosing of rhIGF-1 in children with primary IGF-1 deficiency. Horm Res 2009; 72(suppl 3):103(PO1-113). Program of the 8th Joint Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY (Abstract).
23. Bowlby D, Reiner B, Kuntze J, Hertz J, Frane JW, Blethen S: Long-term safety and efficacy of Increlex treatment: Results from the Increlex growth forum database (IGFD) registry. Horm Res 2009; 72(suppl 3):101(PO1-108). Program of the 8th Joint Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY (Abstract).
24. Midyett LK, Reiner B, Rogol AD, Geffner ME, Frane JW, Bright GM: Preliminary results of a phase II, randomized, open-label, active-treatment controlled trial of rhGH and rhIGF-1 combination therapy in prepubertal children with non-severe primary IGF-1 deficiency. Horm Res 2009; 72(suppl 3):46(FC10-006). Program of the 8th Joint Lawson Wilkins Pediatric Endocrine Society/European Society for Pediatric Endocrinology Meeting, New York, NY (Abstract).
25. Savage MO, Camacho-Hübner C, David A, Metherell LA, Hwa V, Rosenfeld RG, Clark AJ: Idiopathic short stature: Will genetics influence the choice between GH and IGF-I therapy? Eur J Endocrinol 2007; 157(suppl 1):S33-S37. (Pubitemid 47434128)